What is the projected market valuation for the Candidiasis Therapeutics Market in 2035?

The projected market valuation for the Candidiasis Therapeutics Market in 2035 is 6692.03 USD Million. Read More

What was the overall market valuation for the Candidiasis Therapeutics Market in 2024?

The overall market valuation for the Candidiasis Therapeutics Market in 2024 was 3720.44 USD Million. Read More

What is the expected CAGR for the Candidiasis Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR for the Candidiasis Therapeutics Market during the forecast period 2025 - 2035 is 5.48%. Read More

How does the market for Vulvovaginal Candidiasis compare to other indications?

The market for Vulvovaginal Candidiasis is projected to range from 800.0 to 1500.0 USD Million, indicating a substantial segment within the overall market. Read More

What are the primary routes of administration for Candidiasis therapeutics?

The primary routes of administration for Candidiasis therapeutics include Oral, Intravenous, and Topical, with valuations ranging from 1110.11 to 2492.03 USD Million. Read More

Which drug classes dominate the Candidiasis Therapeutics Market?

The dominant drug classes in the Candidiasis Therapeutics Market include Azoles, Echinocandins, Polyene Antifungals, and Allylamines, with valuations between 740.11 and 2000.0 USD Million. Read More

What patient types are primarily targeted in the Candidiasis Therapeutics Market?

The primary patient types targeted in the Candidiasis Therapeutics Market include Immunocompromised Patients, Diabetic Patients, Pregnant Women, and Pediatric Patients, with valuations ranging from 372.04 to 2662.03 USD Million. Read More

What formulations are available for Candidiasis therapeutics?

Available formulations for Candidiasis therapeutics include Tablets, Injectables, Creams, and Suppositories, with market valuations between 740.11 and 2000.0 USD Million. Read More

How does the market for Invasive Candidiasis compare to other segments?

The market for Invasive Candidiasis is projected to range from 1820.44 to 3192.03 USD Million, making it one of the largest segments in the Candidiasis Therapeutics Market. Read More

Candidiasis Therapeutics Market

Q: Which companies are considered key players in the Candidiasis Therapeutics Market?

Key players in the Candidiasis Therapeutics Market include Pfizer Inc, Merck & Co Inc, Gilead Sciences Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc, and F. Hoffmann-La Roche Ltd. Read More

ID: MRFR/HC/7616-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Candidiasis Therapeutics Market Research Report By Drug Class (Azoles, Echinocandins, Polyenes), By Indication (Oral Candidiasis, Vulvovaginal Candidiasis, Invasive Candidiasis), By Route of Administration (Oral, Intravenous, Topical), By Patient Population (Adults, Children, Immunocompromised Patients) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Candidiasis Therapeutics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.48%

2024 Market Size$ 3,720.44 Million

2025 Market Size$ 3,924.4 Million

2035 Market Size$ 6,692.03 Million

Key Players

Pfizer Inc

Merck & Co Inc

Gilead Sciences Inc

Astellas Pharma Inc

Bristol-Myers Squibb Company

Novartis AG

Trends

Rising Incidence of Candidiasis
Advancements in Antifungal Research
Personalized Medicine Approaches

Opportunities

Rising Incidence of Candidiasis
Increased Awareness and Screening
Emerging Markets and Globalization

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Indication (USD Million)
  1. 4.1.1 Oropharyngeal Candidiasis
  2. 4.1.2 Esophageal Candidiasis
  3. 4.1.3 Vulvovaginal Candidiasis
  4. 4.1.4 Invasive Candidiasis
2. 4.2 Healthcare, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Topical
3. 4.3 Healthcare, BY Drug Class (USD Million)
  1. 4.3.1 Azoles
  2. 4.3.2 Echinocandins
  3. 4.3.3 Polyene Antifungals
  4. 4.3.4 Allylamines
4. 4.4 Healthcare, BY Patient Type (USD Million)
  1. 4.4.1 Immunocompromised Patients
  2. 4.4.2 Diabetic Patients
  3. 4.4.3 Pregnant Women
  4. 4.4.4 Pediatric Patients
5. 4.5 Healthcare, BY Formulation Type (USD Million)
  1. 4.5.1 Tablets
  2. 4.5.2 Injectables
  3. 4.5.3 Creams
  4. 4.5.4 Suppositories
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Gilead Sciences Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Astellas Pharma Inc (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 F. Hoffmann-La Roche Ltd (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY INDICATION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY DRUG CLASS
6. 6.6 US MARKET ANALYSIS BY PATIENT TYPE
7. 6.7 US MARKET ANALYSIS BY FORMULATION TYPE
8. 6.8 CANADA MARKET ANALYSIS BY INDICATION
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY DRUG CLASS
11. 6.11 CANADA MARKET ANALYSIS BY PATIENT TYPE
12. 6.12 CANADA MARKET ANALYSIS BY FORMULATION TYPE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY INDICATION
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 GERMANY MARKET ANALYSIS BY DRUG CLASS
17. 6.17 GERMANY MARKET ANALYSIS BY PATIENT TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
19. 6.19 UK MARKET ANALYSIS BY INDICATION
20. 6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
21. 6.21 UK MARKET ANALYSIS BY DRUG CLASS
22. 6.22 UK MARKET ANALYSIS BY PATIENT TYPE
23. 6.23 UK MARKET ANALYSIS BY FORMULATION TYPE
24. 6.24 FRANCE MARKET ANALYSIS BY INDICATION
25. 6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 FRANCE MARKET ANALYSIS BY DRUG CLASS
27. 6.27 FRANCE MARKET ANALYSIS BY PATIENT TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
29. 6.29 RUSSIA MARKET ANALYSIS BY INDICATION
30. 6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 RUSSIA MARKET ANALYSIS BY DRUG CLASS
32. 6.32 RUSSIA MARKET ANALYSIS BY PATIENT TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
34. 6.34 ITALY MARKET ANALYSIS BY INDICATION
35. 6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 ITALY MARKET ANALYSIS BY DRUG CLASS
37. 6.37 ITALY MARKET ANALYSIS BY PATIENT TYPE
38. 6.38 ITALY MARKET ANALYSIS BY FORMULATION TYPE
39. 6.39 SPAIN MARKET ANALYSIS BY INDICATION
40. 6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
41. 6.41 SPAIN MARKET ANALYSIS BY DRUG CLASS
42. 6.42 SPAIN MARKET ANALYSIS BY PATIENT TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY INDICATION
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY INDICATION
51. 6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 CHINA MARKET ANALYSIS BY DRUG CLASS
53. 6.53 CHINA MARKET ANALYSIS BY PATIENT TYPE
54. 6.54 CHINA MARKET ANALYSIS BY FORMULATION TYPE
55. 6.55 INDIA MARKET ANALYSIS BY INDICATION
56. 6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 INDIA MARKET ANALYSIS BY DRUG CLASS
58. 6.58 INDIA MARKET ANALYSIS BY PATIENT TYPE
59. 6.59 INDIA MARKET ANALYSIS BY FORMULATION TYPE
60. 6.60 JAPAN MARKET ANALYSIS BY INDICATION
61. 6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
62. 6.62 JAPAN MARKET ANALYSIS BY DRUG CLASS
63. 6.63 JAPAN MARKET ANALYSIS BY PATIENT TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY INDICATION
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
70. 6.70 MALAYSIA MARKET ANALYSIS BY INDICATION
71. 6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
73. 6.73 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
75. 6.75 THAILAND MARKET ANALYSIS BY INDICATION
76. 6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 THAILAND MARKET ANALYSIS BY DRUG CLASS
78. 6.78 THAILAND MARKET ANALYSIS BY PATIENT TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
80. 6.80 INDONESIA MARKET ANALYSIS BY INDICATION
81. 6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 INDONESIA MARKET ANALYSIS BY DRUG CLASS
83. 6.83 INDONESIA MARKET ANALYSIS BY PATIENT TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
85. 6.85 REST OF APAC MARKET ANALYSIS BY INDICATION
86. 6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
88. 6.88 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY INDICATION
92. 6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 BRAZIL MARKET ANALYSIS BY DRUG CLASS
94. 6.94 BRAZIL MARKET ANALYSIS BY PATIENT TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
96. 6.96 MEXICO MARKET ANALYSIS BY INDICATION
97. 6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 MEXICO MARKET ANALYSIS BY DRUG CLASS
99. 6.99 MEXICO MARKET ANALYSIS BY PATIENT TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
101. 6.101 ARGENTINA MARKET ANALYSIS BY INDICATION
102. 6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
104. 6.104 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
122. 6.122 REST OF MEA MARKET ANALYSIS BY INDICATION
123. 6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
125. 6.125 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.2.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.3.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.3.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.4.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.4.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.5.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.5.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.6.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.6.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.7.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.7.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.8.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.8.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.9.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.9.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.10.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.10.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.11.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.11.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.12.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.12.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.13.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.13.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.14.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.14.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.15.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.15.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.16.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.16.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.17.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.17.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.18.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.18.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.19.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.19.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.20.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.20.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.21.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.21.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.22.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.22.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.23.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.23.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.24.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.24.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.25.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.25.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.26.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.26.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.27.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.27.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.28.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.28.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.29.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.29.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY INDICATION, 2025-2035 (USD Million)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.30.3 BY DRUG CLASS, 2025-2035 (USD Million)
  4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Million)
  5. 7.30.5 BY FORMULATION TYPE, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Candidiasis Therapeutics Market Segmentation

Candidiasis Therapeutics Market By Indication (USD Million, 2025-2035)

Oropharyngeal Candidiasis
Esophageal Candidiasis
Vulvovaginal Candidiasis
Invasive Candidiasis

Candidiasis Therapeutics Market By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Topical

Candidiasis Therapeutics Market By Drug Class (USD Million, 2025-2035)

Azoles
Echinocandins
Polyene Antifungals
Allylamines

Candidiasis Therapeutics Market By Patient Type (USD Million, 2025-2035)

Immunocompromised Patients
Diabetic Patients
Pregnant Women
Pediatric Patients

Candidiasis Therapeutics Market By Formulation Type (USD Million, 2025-2035)

Tablets
Injectables
Creams
Suppositories

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”